Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to ...

Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...

Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...

The FDA has granted Priority Review to pegcetacoplan for the treatment of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...

IgAN is a progressive, rare kidney disease in which the immune system attacks the kidneys, often causing glomerular ...

At Opelousas General Health, a special event was held to honor those who have received life-saving organ transplants, shining a light on the incredible impact of organ donation.

A form of membranoproliferative glomerulonephritis, this ultra-rare disease affects roughly 2 to 3 out of every 1 million people. Because of damage to kidney glomeruli, people with C3G can ...

High blood pressure, chills, and fatigue accompanied this young man's weight increase, as well as swelling.

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...

Scotiabank raised the firm’s price target on Apellis (APLS) to $31 from $30 and keeps a Sector Perform rating on the shares. The company ...